JP2009532486A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2009532486A5 JP2009532486A5 JP2009504315A JP2009504315A JP2009532486A5 JP 2009532486 A5 JP2009532486 A5 JP 2009532486A5 JP 2009504315 A JP2009504315 A JP 2009504315A JP 2009504315 A JP2009504315 A JP 2009504315A JP 2009532486 A5 JP2009532486 A5 JP 2009532486A5
- Authority
- JP
- Japan
- Prior art keywords
- substituted
- alkyl
- heteroaryl
- amino
- tautomer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- -1 carbonylamino, aminocarbonyl Chemical group 0.000 claims description 75
- 125000000217 alkyl group Chemical group 0.000 claims description 54
- 125000001072 heteroaryl group Chemical group 0.000 claims description 53
- 150000001875 compounds Chemical class 0.000 claims description 45
- 150000003839 salts Chemical class 0.000 claims description 45
- 125000000623 heterocyclic group Chemical group 0.000 claims description 34
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 32
- 125000000547 substituted alkyl group Chemical group 0.000 claims description 24
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 22
- 125000005843 halogen group Chemical group 0.000 claims description 20
- 125000003545 alkoxy group Chemical group 0.000 claims description 18
- 125000003118 aryl group Chemical group 0.000 claims description 18
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 18
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 claims description 18
- 125000004414 alkyl thio group Chemical group 0.000 claims description 16
- 125000003107 substituted aryl group Chemical group 0.000 claims description 16
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 14
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 13
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 12
- 125000002252 acyl group Chemical group 0.000 claims description 10
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims description 10
- 125000005844 heterocyclyloxy group Chemical group 0.000 claims description 10
- 125000005415 substituted alkoxy group Chemical group 0.000 claims description 10
- 125000005346 substituted cycloalkyl group Chemical group 0.000 claims description 10
- 125000004442 acylamino group Chemical group 0.000 claims description 8
- 125000004423 acyloxy group Chemical group 0.000 claims description 8
- 125000003342 alkenyl group Chemical group 0.000 claims description 8
- 125000004183 alkoxy alkyl group Chemical group 0.000 claims description 8
- 125000000304 alkynyl group Chemical group 0.000 claims description 8
- 125000004104 aryloxy group Chemical group 0.000 claims description 8
- 125000005553 heteroaryloxy group Chemical group 0.000 claims description 8
- 125000004415 heterocyclylalkyl group Chemical group 0.000 claims description 8
- 229910052757 nitrogen Inorganic materials 0.000 claims description 8
- 125000001820 oxy group Chemical group [*:1]O[*:2] 0.000 claims description 8
- 125000005017 substituted alkenyl group Chemical group 0.000 claims description 8
- 125000004426 substituted alkynyl group Chemical group 0.000 claims description 8
- 125000003441 thioacyl group Chemical group 0.000 claims description 8
- 150000003573 thiols Chemical class 0.000 claims description 8
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 6
- 125000002947 alkylene group Chemical group 0.000 claims description 4
- 125000004682 aminothiocarbonyl group Chemical group NC(=S)* 0.000 claims description 4
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims description 4
- 229910052799 carbon Inorganic materials 0.000 claims description 4
- 125000006297 carbonyl amino group Chemical group [H]N([*:2])C([*:1])=O 0.000 claims description 4
- 125000004122 cyclic group Chemical group 0.000 claims description 4
- 125000000000 cycloalkoxy group Chemical group 0.000 claims description 4
- 229910052739 hydrogen Inorganic materials 0.000 claims description 4
- 125000005338 substituted cycloalkoxy group Chemical group 0.000 claims description 4
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 2
- 229910052736 halogen Inorganic materials 0.000 claims description 2
- 150000002367 halogens Chemical class 0.000 claims description 2
- 125000005842 heteroatom Chemical group 0.000 claims description 2
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 2
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 2
- 229910052760 oxygen Inorganic materials 0.000 claims description 2
- 125000001424 substituent group Chemical group 0.000 claims description 2
- 229910052717 sulfur Inorganic materials 0.000 claims description 2
- 239000003814 drug Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 0 COC1CCN(*)CC1 Chemical compound COC1CCN(*)CC1 0.000 description 2
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 description 1
- 125000004214 1-pyrrolidinyl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 101000600756 Homo sapiens 3-phosphoinositide-dependent protein kinase 1 Proteins 0.000 description 1
- 101001117146 Homo sapiens [Pyruvate dehydrogenase (acetyl-transferring)] kinase isozyme 1, mitochondrial Proteins 0.000 description 1
- 102100024148 [Pyruvate dehydrogenase (acetyl-transferring)] kinase isozyme 1, mitochondrial Human genes 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US79030406P | 2006-04-06 | 2006-04-06 | |
| PCT/US2007/008592 WO2007117607A2 (en) | 2006-04-06 | 2007-04-05 | Quinazolines for pdk1 inhibition |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2009532486A JP2009532486A (ja) | 2009-09-10 |
| JP2009532486A5 true JP2009532486A5 (enExample) | 2010-03-11 |
Family
ID=38476139
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009504315A Withdrawn JP2009532486A (ja) | 2006-04-06 | 2007-04-05 | Ｐｄｋ１阻害のためのキナゾリン類 |
Country Status (22)
| Country | Link |
|---|---|
| US (1) | US7932262B2 (enExample) |
| EP (1) | EP2004615A2 (enExample) |
| JP (1) | JP2009532486A (enExample) |
| KR (1) | KR20080111114A (enExample) |
| CN (1) | CN101454294A (enExample) |
| AR (1) | AR060358A1 (enExample) |
| AU (1) | AU2007235339A1 (enExample) |
| BR (1) | BRPI0710521A2 (enExample) |
| CA (1) | CA2648529A1 (enExample) |
| CR (1) | CR10427A (enExample) |
| EA (1) | EA200870415A1 (enExample) |
| EC (1) | ECSP088823A (enExample) |
| GT (1) | GT200800202A (enExample) |
| MA (1) | MA30358B1 (enExample) |
| MX (1) | MX2008012852A (enExample) |
| NO (1) | NO20084665L (enExample) |
| PE (1) | PE20080059A1 (enExample) |
| SM (1) | SMP200800059B (enExample) |
| TN (1) | TNSN08375A1 (enExample) |
| TW (1) | TW200808739A (enExample) |
| WO (1) | WO2007117607A2 (enExample) |
| ZA (1) | ZA200808307B (enExample) |
Families Citing this family (60)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2673003A1 (en) * | 2006-12-22 | 2008-07-03 | Novartis Ag | Quinazolines for pdk1 inhibition |
| UY31137A1 (es) * | 2007-06-14 | 2009-01-05 | Smithkline Beecham Corp | Derivados de quinazolina como inhibidores de la pi3 quinasa |
| US8389531B2 (en) | 2007-07-11 | 2013-03-05 | Hetero Drugs Limited | Process for erlotinib hydrochloride |
| WO2009084695A1 (ja) | 2007-12-28 | 2009-07-09 | Carna Biosciences Inc. | ２－アミノキナゾリン誘導体 |
| ATE535515T1 (de) * | 2008-01-11 | 2011-12-15 | Hoffmann La Roche | Modulatoren für amyloid beta |
| US20110039845A1 (en) | 2008-04-23 | 2011-02-17 | Kyowa Hakko Kirin Co., Ltd. | 2-aminoquinazoline derivative |
| AU2009248774B2 (en) | 2008-05-23 | 2012-05-31 | Novartis Ag | Derivatives of quinolines and quinoxalines as protein tyrosine kinase inhibitors |
| JP5599783B2 (ja) | 2008-05-30 | 2014-10-01 | アムジエン・インコーポレーテツド | Ｐｉ３キナーゼの阻害薬 |
| US20100121052A1 (en) * | 2008-06-20 | 2010-05-13 | Rama Jain | Novel compounds for treating proliferative diseases |
| CA2748319A1 (en) * | 2008-12-29 | 2010-07-08 | Fovea Pharmaceuticals | Substituted quinazoline compounds of general formula (i) and uses thereof for treating disorders relating to tyrosine kinase dysregulation |
| WO2012044090A2 (ko) * | 2010-09-29 | 2012-04-05 | 크리스탈지노믹스(주) | 단백질 키나제 억제 활성을 갖는 신규한 아미노퀴나졸린 화합물 |
| WO2013050527A1 (en) | 2011-10-05 | 2013-04-11 | H. Lundbeck A/S | Quinazoline derivatives as pde10a enzyme inhibitors |
| KR101360948B1 (ko) * | 2012-01-17 | 2014-02-12 | 한국과학기술연구원 | 신규한 2-아미노퀴나졸린 유도체 및 이를 유효성분으로 포함하는 항암제 |
| GB201216017D0 (en) | 2012-09-07 | 2012-10-24 | Cancer Rec Tech Ltd | Inhibitor compounds |
| ES3069593T3 (en) * | 2013-08-23 | 2026-06-09 | Neupharma Inc | Quinazolin-8-yl derivatives for use in methods of treating melanoma, non-small cell lung cancer, thyroid cancer, ovarian cancer, or colon cancer |
| EP3078660B1 (en) * | 2013-12-06 | 2022-07-13 | MycHunter Therapeutics, Inc. | Novel quinazoline derivative |
| US9815797B2 (en) * | 2013-12-09 | 2017-11-14 | Ucb Biopharma Sprl | Fused bicyclic heteroaromatic derivatives as modulators of TNF activity |
| GB201403536D0 (en) | 2014-02-28 | 2014-04-16 | Cancer Rec Tech Ltd | Inhibitor compounds |
| BR112016022056B1 (pt) | 2014-03-26 | 2023-04-11 | Astex Therapeutics Limited | Combinação, composição farmacêutica, uso de uma combinação ou uma composição farmacêutica, e, produto farmacêutico |
| JP6225358B2 (ja) | 2014-09-01 | 2017-11-08 | 日本曹達株式会社 | ２−アミノ置換ベンズアルデヒド化合物を製造する方法 |
| TWI770552B (zh) | 2014-12-24 | 2022-07-11 | 美商基利科學股份有限公司 | 喹唑啉化合物 |
| CA2972014C (en) | 2014-12-24 | 2019-09-24 | Gilead Sciences, Inc. | Fused pyrimidine compounds for the treatment of hiv |
| SG11201705184PA (en) | 2014-12-24 | 2017-07-28 | Gilead Sciences Inc | Isoquinoline compounds for the treatment of hiv |
| TWI719960B (zh) | 2015-02-10 | 2021-03-01 | 英商阿斯迪克治療公司 | 新穎組成物 |
| EP3270694A4 (en) * | 2015-02-17 | 2018-09-05 | Neupharma, Inc. | Certain chemical entities, compositions, and methods |
| US10478494B2 (en) | 2015-04-03 | 2019-11-19 | Astex Therapeutics Ltd | FGFR/PD-1 combination therapy for the treatment of cancer |
| WO2017005137A1 (zh) * | 2015-07-03 | 2017-01-12 | 吉林大学 | 喹唑啉类化合物、其中间体、制备方法、药物组合物和应用 |
| US10494378B2 (en) * | 2015-07-21 | 2019-12-03 | Guangzhou Maxinovel Pharmaceuticals Co., Ltd. | Fused ring pyrimidine compound, intermediate, and preparation method, composition and use thereof |
| ES2967344T3 (es) | 2015-10-02 | 2024-04-29 | Sentinel Oncology Ltd | Derivados de 2-aminoquinazolina como inhibidores de cinasa p70s6 |
| CN105753793B (zh) * | 2016-01-19 | 2018-09-04 | 河北医科大学 | 芳甲酰脲偶联喹唑啉类化合物及其制备方法、药物组合物及药物用途 |
| CN109843858B (zh) | 2016-08-15 | 2023-05-05 | 润新生物公司 | 某些化学实体、组合物及方法 |
| GB201705263D0 (en) * | 2017-03-31 | 2017-05-17 | Probiodrug Ag | Novel inhibitors |
| GB201709840D0 (en) | 2017-06-20 | 2017-08-02 | Inst Of Cancer Research: Royal Cancer Hospital | Methods and medical uses |
| RU2761824C2 (ru) * | 2018-08-03 | 2021-12-13 | Закрытое Акционерное Общество "Биокад" | Ингибиторы CDK8/19 |
| CN110872243B (zh) * | 2018-08-31 | 2023-03-31 | 四川科伦博泰生物医药股份有限公司 | 磺酰胺类化合物、其制备方法及用途 |
| CN109320511A (zh) * | 2018-10-26 | 2019-02-12 | 广安凯特制药有限公司 | 一种高纯度帕博西尼中间体产品及其制备方法 |
| JP2022535086A (ja) * | 2019-06-05 | 2022-08-04 | アドバンスド テクノロジーズ フォー ノベル セラピューティクス，エルエルシー | 修飾ペプチドおよび関連する使用方法 |
| EP4090663A1 (en) * | 2020-01-15 | 2022-11-23 | Blueprint Medicines Corporation | Map4k1 inhibitors |
| WO2021180032A1 (en) * | 2020-03-13 | 2021-09-16 | Guangzhou Maxinovel Pharmaceuticals Co., Ltd. | Novel Therapeutic Methods |
| CN114315798B (zh) * | 2020-09-29 | 2025-03-25 | 安思科(苏州)医药科技有限公司 | 喹唑啉类化合物及其药物组合物 |
| EP4240361A4 (en) * | 2020-11-09 | 2024-09-25 | Merck Sharp & Dohme LLC | INHIBITORS, OF THE 7-AZOLE SUBSTITUTED 2-AMINOQUINAZOLINE TYPE, OF HPK1 |
| EP4240363A4 (en) * | 2020-11-09 | 2024-10-23 | Merck Sharp & Dohme LLC | 2-AMINOQUINAZOLINE 7-PHENYL SUBSTITUTED, HPK1 INHIBITORS |
| JP2024511012A (ja) * | 2021-03-24 | 2024-03-12 | アトス セラピューティクス，インコーポレイテッド | キナーゼ関連疾患の処置のための小分子 |
| WO2022222951A1 (zh) * | 2021-04-22 | 2022-10-27 | 浙江海正药业股份有限公司 | 芳香稠合环类衍生物及其制备方法和用途 |
| CN115583946B (zh) * | 2021-07-06 | 2026-01-16 | 赛诺哈勃药业（成都）有限公司 | 杂环化合物及其作为cdk抑制剂的用途 |
| CN113999206B (zh) * | 2021-12-31 | 2022-04-12 | 北京鑫开元医药科技有限公司 | 异喹啉-1,3-二胺类似物、制备方法、药物组合物及其应用 |
| CN114533733A (zh) * | 2021-12-31 | 2022-05-27 | 北京鑫开元医药科技有限公司 | 一种异喹啉-1,3-二胺类似物药物制剂及其制备方法 |
| WO2023138412A1 (en) * | 2022-01-20 | 2023-07-27 | Insilico Medicine Ip Limited | Fused pyrimidin-2-amine compounds as cdk20 inhibitors |
| WO2023143135A1 (zh) * | 2022-01-28 | 2023-08-03 | 赛诺哈勃药业（成都）有限公司 | 一种喹唑啉衍生物及其用途 |
| CN116672450A (zh) * | 2022-02-23 | 2023-09-01 | 智宠制药（北京）有限公司 | Hpk1抑制剂在治疗干扰素相关疾病中的应用 |
| WO2023218241A1 (en) * | 2022-05-13 | 2023-11-16 | Voronoi Inc. | Heteroaryl derivative compounds, and pharmaceutical composition comprising thereof |
| WO2024020380A1 (en) * | 2022-07-18 | 2024-01-25 | Iambic Therapeutics, Inc. | Quinazoline compounds and methods of use |
| WO2024131938A1 (zh) * | 2022-12-23 | 2024-06-27 | 赛诺哈勃药业（成都）有限公司 | 喹唑啉类化合物及其用途 |
| WO2024186579A1 (en) * | 2023-03-03 | 2024-09-12 | Deliver Therapeutics, Inc. | Protein kinase inhibitors and uses thereof |
| KR20250027005A (ko) | 2023-08-18 | 2025-02-25 | 인하대학교 산학협력단 | Itgb4 억제 활성을 나타내는 화합물을 유효성분으로 포함하는 심혈관계 질환 예방 또는 치료용 약학 조성물 |
| PY2501648A (es) | 2024-01-12 | 2025-10-31 | Syngenta Crop Protection Ag | Nuevos compuestos de carboxamida |
| WO2025155742A1 (en) * | 2024-01-17 | 2025-07-24 | Iambic Therapeutics, Inc. | Methods of use for quinazoline compounds |
| WO2026008750A1 (en) | 2024-07-05 | 2026-01-08 | Syngenta Crop Protection Ag | Novel carboxamide compounds |
| WO2026050773A1 (en) * | 2024-09-02 | 2026-03-05 | Deliver Therapeutics, Inc. | Protein kinase inhibitors and uses thereof |
| WO2026119962A1 (en) | 2024-12-04 | 2026-06-11 | Syngenta Crop Protection Ag | Novel phenyl carboxamide compounds |
Family Cites Families (80)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US73044A (en) | 1868-01-07 | John c | ||
| US171303A (en) | 1875-12-21 | Improvement in corn-stalk knives | ||
| US134846A (en) | 1873-01-14 | Half his eight to william h | ||
| JPS6041077B2 (ja) * | 1976-09-06 | 1985-09-13 | 喜徳 喜谷 | １，２‐ジアミノシクロヘキサン異性体のシス白金（２）錯体 |
| US4323581A (en) * | 1978-07-31 | 1982-04-06 | Johnson & Johnson | Method of treating carcinogenesis |
| IL73534A (en) * | 1983-11-18 | 1990-12-23 | Riker Laboratories Inc | 1h-imidazo(4,5-c)quinoline-4-amines,their preparation and pharmaceutical compositions containing certain such compounds |
| WO1988007045A1 (fr) | 1987-03-09 | 1988-09-22 | Kyowa Hakko Kogyo Co., Ltd. | Derives de la substance physiologiquement active k-252 |
| US4904768A (en) * | 1987-08-04 | 1990-02-27 | Bristol-Myers Company | Epipodophyllotoxin glucoside 4'-phosphate derivatives |
| EP0383919A4 (en) | 1988-02-04 | 1992-08-05 | Kyowa Hakko Kogyo Co., Ltd. | Staurosporin derivatives |
| US5238944A (en) * | 1988-12-15 | 1993-08-24 | Riker Laboratories, Inc. | Topical formulations and transdermal delivery systems containing 1-isobutyl-1H-imidazo[4,5-c]quinolin-4-amine |
| US4929624A (en) * | 1989-03-23 | 1990-05-29 | Minnesota Mining And Manufacturing Company | Olefinic 1H-imidazo(4,5-c)quinolin-4-amines |
| US5389640A (en) * | 1991-03-01 | 1995-02-14 | Minnesota Mining And Manufacturing Company | 1-substituted, 2-substituted 1H-imidazo[4,5-c]quinolin-4-amines |
| US6410010B1 (en) | 1992-10-13 | 2002-06-25 | Board Of Regents, The University Of Texas System | Recombinant P53 adenovirus compositions |
| US5268376A (en) * | 1991-09-04 | 1993-12-07 | Minnesota Mining And Manufacturing Company | 1-substituted 1H-imidazo[4,5-c]quinolin-4-amines |
| EP0540185A1 (en) | 1991-10-10 | 1993-05-05 | Schering Corporation | 4'-(N-substituted-N-oxide)staurosporine derivatives |
| US5266575A (en) * | 1991-11-06 | 1993-11-30 | Minnesota Mining And Manufacturing Company | 2-ethyl 1H-imidazo[4,5-ciquinolin-4-amines |
| AU3064992A (en) | 1991-11-08 | 1993-06-07 | University Of Southern California | Compositions containing k-252 compounds for potentiation of neurotrophin activity |
| AU661533B2 (en) * | 1992-01-20 | 1995-07-27 | Astrazeneca Ab | Quinazoline derivatives |
| US5948898A (en) | 1992-03-16 | 1999-09-07 | Isis Pharmaceuticals, Inc. | Methoxyethoxy oligonucleotides for modulation of protein kinase C expression |
| IL105325A (en) * | 1992-04-16 | 1996-11-14 | Minnesota Mining & Mfg | Immunogen/vaccine adjuvant composition |
| US5621100A (en) * | 1992-07-24 | 1997-04-15 | Cephalon, Inc. | K-252a derivatives for treatment of neurological disorders |
| US5756494A (en) | 1992-07-24 | 1998-05-26 | Cephalon, Inc. | Protein kinase inhibitors for treatment of neurological disorders |
| ES2225824T3 (es) | 1992-08-31 | 2005-03-16 | Ludwig Institute For Cancer Research | Nonapeptido aislado derivado del gen mage-3 y presentado por hla-a1, y sus usos. |
| DE69331228T4 (de) | 1992-09-21 | 2002-09-05 | Kyowa Hakko Kogyo Co., Ltd. | Heilmittel für thrombozytopenia |
| KR100335584B1 (ko) | 1992-10-28 | 2002-11-29 | 제넨테크, 인코포레이티드 | 혈관내피세포성장인자에대한길항제 |
| US5395937A (en) * | 1993-01-29 | 1995-03-07 | Minnesota Mining And Manufacturing Company | Process for preparing quinoline amines |
| US5352784A (en) * | 1993-07-15 | 1994-10-04 | Minnesota Mining And Manufacturing Company | Fused cycloalkylimidazopyridines |
| DK0708772T3 (da) * | 1993-07-15 | 2000-09-18 | Minnesota Mining & Mfg | Imidazo[4,5,-c]pyridin-4-aminer |
| US5478932A (en) * | 1993-12-02 | 1995-12-26 | The Board Of Trustees Of The University Of Illinois | Ecteinascidins |
| EP1449529B1 (en) | 1993-12-23 | 2010-01-27 | Eli Lilly And Company | Protein Kinase C Inhibitors |
| US5525613A (en) * | 1994-06-16 | 1996-06-11 | Entropin, Inc. | Covalently coupled benzoylecgonine ecgonine and ecgonidine |
| US5587459A (en) | 1994-08-19 | 1996-12-24 | Regents Of The University Of Minnesota | Immunoconjugates comprising tyrosine kinase inhibitors |
| US6083903A (en) * | 1994-10-28 | 2000-07-04 | Leukosite, Inc. | Boronic ester and acid compounds, synthesis and uses |
| US5482936A (en) * | 1995-01-12 | 1996-01-09 | Minnesota Mining And Manufacturing Company | Imidazo[4,5-C]quinoline amines |
| ATE446955T1 (de) | 1995-03-30 | 2009-11-15 | Pfizer Prod Inc | Chinazolinone derivate |
| GB9508538D0 (en) * | 1995-04-27 | 1995-06-14 | Zeneca Ltd | Quinazoline derivatives |
| US6331555B1 (en) * | 1995-06-01 | 2001-12-18 | University Of California | Treatment of platelet derived growth factor related disorders such as cancers |
| US5747498A (en) * | 1996-05-28 | 1998-05-05 | Pfizer Inc. | Alkynyl and azido-substituted 4-anilinoquinazolines |
| US5880141A (en) * | 1995-06-07 | 1999-03-09 | Sugen, Inc. | Benzylidene-Z-indoline compounds for the treatment of disease |
| WO1997007081A2 (en) | 1995-08-11 | 1997-02-27 | Yale University | Glycosylated indolocarbazole synthesis |
| FR2741881B1 (fr) | 1995-12-01 | 1999-07-30 | Centre Nat Rech Scient | Nouveaux derives de purine possedant notamment des prorietes anti-proliferatives et leurs applications biologiques |
| DE69635966T2 (de) | 1995-12-08 | 2006-11-30 | Janssen Pharmaceutica N.V. | (Imidazol-5-yl)Methyl-2-Chinolinonderivate als Farnesyl Protein transferase Inhibitoren |
| KR100447918B1 (ko) * | 1996-07-25 | 2005-09-28 | 동아제약주식회사 | 대장을포함한위장관보호작용을갖는플라본및플라바논화합물 |
| CN1189562C (zh) | 1996-08-02 | 2005-02-16 | 吉倪塞思技术公司 | 针对核糖核苷酸还原酶r1和r2组分的抗肿瘤反义序列 |
| CO4950519A1 (es) * | 1997-02-13 | 2000-09-01 | Novartis Ag | Ftalazinas, preparaciones farmaceuticas que las comprenden y proceso para su preparacion |
| US6126965A (en) | 1997-03-21 | 2000-10-03 | Georgetown University School Of Medicine | Liposomes containing oligonucleotides |
| EP1017394B1 (en) | 1997-07-12 | 2005-12-07 | Cancer Research Technology Limited | Cyclin dependent kinase inhibiting purine derivatives |
| RS49779B (sr) * | 1998-01-12 | 2008-06-05 | Glaxo Group Limited, | Biciklična heteroaromatična jedinjenja kao inhibitori protein tirozin kinaze |
| KR100743287B1 (ko) | 1998-05-29 | 2007-07-26 | 수젠, 인크. | 피롤기로 치환된 2-인돌리논 단백질 인산화 효소 억제제 |
| US20030083242A1 (en) | 1998-11-06 | 2003-05-01 | Alphonse Galdes | Methods and compositions for treating or preventing peripheral neuropathies |
| AR024464A1 (es) | 1999-06-25 | 2002-10-02 | Genentech Inc | Anticuerpos anti-erbb2 humanizados. |
| AU6014900A (en) | 1999-07-13 | 2001-01-30 | Kyowa Hakko Kogyo Co. Ltd. | Staurosporin derivatives |
| PT1244647E (pt) | 1999-11-05 | 2006-10-31 | Astrazeneca Ab | Derivados de quinazolina como inibidores de vegf |
| CA2386955A1 (en) * | 1999-11-22 | 2001-05-31 | Warner-Lambert Company | Quinazolines and their use for inhibiting cyclin-dependent kinase enzymes |
| US6982260B1 (en) * | 1999-11-22 | 2006-01-03 | Warner-Lambert Company | Quinazolines and their use for inhibiting cyclin-dependent kinase enzymes |
| HRP20020751B1 (hr) | 2000-02-15 | 2011-01-31 | Sugen | Pirolom supstituirani 2-indolinoni kao inhibitori protein kinaze |
| EP1274718B1 (en) | 2000-04-12 | 2006-10-18 | Genaera Corporation | A process for the preparation of 7.alpha.-hydroxy 3-aminosubstituted sterols using intermediates with an unprotected 7.alpha.-hydroxy group |
| CA2413134C (en) | 2000-06-30 | 2010-05-11 | Glaxo Group Limited | Quinazoline ditosylate salt compounds |
| BRPI0113757B8 (pt) * | 2000-09-11 | 2017-11-07 | Chiron Corp | derivados de quinolinona como inibidores de tirosina quinase |
| US6677450B2 (en) | 2000-10-06 | 2004-01-13 | Bristol-Myers Squibb Company | Topoisomerase inhibitors |
| ATE325865T1 (de) | 2001-01-16 | 2006-06-15 | Regeneron Pharma | Isolierung von sezernierte proteine exprimierenden zellen |
| WO2002062826A1 (fr) | 2001-02-07 | 2002-08-15 | Vadim Viktorovich Novikov | Procede de fabrication des peptides |
| EP1404689A1 (en) | 2001-07-02 | 2004-04-07 | Debiopharm S.A. | Oxaliplatin active substance with a very low content of oxalic acid |
| KR100484504B1 (ko) | 2001-09-18 | 2005-04-20 | 학교법인 포항공과대학교 | 쿠커비투릴 유도체를 주인 분자로서 포함하고 있는 내포화합물 및 이를 포함한 약제학적 조성물 |
| US20030134846A1 (en) * | 2001-10-09 | 2003-07-17 | Schering Corporation | Treatment of trypanosoma brucei with farnesyl protein transferase inhibitors |
| TW200306819A (en) | 2002-01-25 | 2003-12-01 | Vertex Pharma | Indazole compounds useful as protein kinase inhibitors |
| US6927036B2 (en) * | 2002-02-19 | 2005-08-09 | Xero Port, Inc. | Methods for synthesis of prodrugs from 1-acyl-alkyl derivatives and compositions thereof |
| MXPA04009541A (es) | 2002-03-29 | 2005-01-25 | Chiron Corp | Benzazoles sustituidos y uso de los mismos como inhibidores de cinasa raf. |
| US6900342B2 (en) * | 2002-05-10 | 2005-05-31 | Dabur India Limited | Anticancer taxanes such as paclitaxel, docetaxel and their structural analogs, and a method for the preparation thereof |
| US6727272B1 (en) | 2002-07-15 | 2004-04-27 | Unitech Pharmaceuticals, Inc. | Leflunomide analogs for treating rheumatoid arthritis |
| US7148342B2 (en) | 2002-07-24 | 2006-12-12 | The Trustees Of The University Of Pennyslvania | Compositions and methods for sirna inhibition of angiogenesis |
| CA2511646A1 (en) | 2002-12-27 | 2004-07-22 | Chiron Corporation | Thiosemicarbazones as anti-virals and immunopotentiators |
| EP1590341B1 (en) | 2003-01-17 | 2009-06-17 | Warner-Lambert Company LLC | 2-aminopyridine substituted heterocycles as inhibitors of cellular proliferation |
| WO2004064759A2 (en) | 2003-01-21 | 2004-08-05 | Chiron Corporation | Use of tryptanthrin compounds for immune potentiation |
| WO2004087153A2 (en) | 2003-03-28 | 2004-10-14 | Chiron Corporation | Use of organic compounds for immunopotentiation |
| WO2005030776A1 (en) | 2003-09-23 | 2005-04-07 | Vertex Pharmaceuticals Incorporated | Pyrazolopyrrole derivatives as protein kinase inhibitors |
| AU2005284835A1 (en) | 2004-09-14 | 2006-03-23 | Novartis Vaccines And Diagnostics Inc. | Imidazoquinoline compounds |
| EP1878727A4 (en) * | 2005-04-28 | 2013-11-13 | Kyowa Hakko Kirin Co Ltd | 2-AMINOQUINAZOLINE DERIVATIVES |
| WO2006137421A1 (ja) * | 2005-06-21 | 2006-12-28 | Kyowa Hakko Kogyo Co., Ltd. | 局所投与剤 |
| JO2660B1 (en) | 2006-01-20 | 2012-06-17 | نوفارتيس ايه جي | Pi-3 inhibitors and methods of use |
-
2007
- 2007-04-04 TW TW096112158A patent/TW200808739A/zh unknown
- 2007-04-04 AR ARP070101448A patent/AR060358A1/es unknown
- 2007-04-05 BR BRPI0710521-5A patent/BRPI0710521A2/pt not_active IP Right Cessation
- 2007-04-05 CN CNA2007800195027A patent/CN101454294A/zh active Pending
- 2007-04-05 JP JP2009504315A patent/JP2009532486A/ja not_active Withdrawn
- 2007-04-05 MX MX2008012852A patent/MX2008012852A/es not_active Application Discontinuation
- 2007-04-05 EA EA200870415A patent/EA200870415A1/ru unknown
- 2007-04-05 AU AU2007235339A patent/AU2007235339A1/en not_active Abandoned
- 2007-04-05 US US12/295,967 patent/US7932262B2/en not_active Expired - Fee Related
- 2007-04-05 KR KR1020087026508A patent/KR20080111114A/ko not_active Withdrawn
- 2007-04-05 CA CA002648529A patent/CA2648529A1/en not_active Abandoned
- 2007-04-05 EP EP07755008A patent/EP2004615A2/en not_active Withdrawn
- 2007-04-05 SM SM200800059T patent/SMP200800059B/it unknown
- 2007-04-05 WO PCT/US2007/008592 patent/WO2007117607A2/en not_active Ceased
- 2007-04-09 PE PE2007000418A patent/PE20080059A1/es not_active Application Discontinuation
-
2008
- 2008-09-25 TN TNP2008000375A patent/TNSN08375A1/en unknown
- 2008-09-29 ZA ZA200808307A patent/ZA200808307B/xx unknown
- 2008-10-01 GT GT200800202A patent/GT200800202A/es unknown
- 2008-10-15 EC EC2008008823A patent/ECSP088823A/es unknown
- 2008-10-27 MA MA31336A patent/MA30358B1/fr unknown
- 2008-11-05 CR CR10427A patent/CR10427A/es not_active Application Discontinuation
- 2008-11-05 NO NO20084665A patent/NO20084665L/no not_active Application Discontinuation
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2397168C2 (ru) | Производные тиофена в качестве ингибиторов снк 1 | |
| RU2020113549A (ru) | Агент, контролирующий эктопаразитов, длительного действия для животного | |
| JP2018502912A5 (enExample) | ||
| JP2006515858A5 (enExample) | ||
| JP2014511892A5 (enExample) | ||
| JP2018502925A5 (enExample) | ||
| RU2017144495A (ru) | Противогельминтные депсипептидные соединения | |
| JP2011515398A5 (enExample) | ||
| JP2019516755A5 (enExample) | ||
| JP2014511891A5 (enExample) | ||
| JP2016506960A5 (enExample) | ||
| JP2011520792A5 (enExample) | ||
| JP2013537203A5 (enExample) | ||
| CA2503868A1 (en) | Sulfonamides, sulfamates and sulfamides as gamma-secretase inhibitors | |
| JP2016505586A5 (enExample) | ||
| RU2012116584A (ru) | Лизинспецифические ингибиторы деметилазы-1 и их применение | |
| JP2012516871A5 (enExample) | ||
| RU2007134380A (ru) | Антибактериальные производные пиперидина | |
| RU2014103587A (ru) | Производные циклических аминов в качестве антагонистов рецептора ер4 | |
| JP2016506961A5 (enExample) | ||
| JP2011526913A5 (ja) | キナゾリン化合物及び同化合物を含む治療薬 | |
| JP2021510733A5 (enExample) | ||
| RU2016135922A (ru) | Терапевтические соединения и композиции | |
| JP2015500842A5 (enExample) | ||
| AR046942A1 (es) | Arilpirazoles sustituidos, un procedimiento para su preparacion, composiciones farmaceuticas o veterinarias que los contienen como principio activo y su uso en la fabricacion de un medicamento parasiticida humano o animal. |